CML patients in England win access to Incyte’s Iclusig

2nd May 2017 Uncategorised 0

Chronic Myeloid Leukaemia (CML) patients in England who are resistant or intolerant to second generation tyrosine kinase inhibitor (TKI) therapies are on the brink of getting full-access to Incyte’s Iclusig on the NHS following a nod from NICE.

More: CML patients in England win access to Incyte’s Iclusig
Source: News